MedTrace Logo

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-04-21

No results posted yet for this study

Summary

Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals.

Conditions

  • Nonexudative Age-related Macular Degeneration

Interventions

DRUG

MC-1101, Placebo

One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo

Sponsors & Collaborators

  • MacuCLEAR, Inc.

    lead INDUSTRY

Principal Investigators

  • Ken Sall, MD · Sall Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01922128 on ClinicalTrials.gov